EUCTR2007-002016-26-IS进行中（未招募）不适用
A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer. The Synergism Or Long Duration (SOLD) Study. - SOLD
Finnish Braest Cancer Group0 个研究点目标入组 3,000 人开始时间: 2009年12月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
The Synergism Or Long Duration (SOLD) Studybreast cancerCTIS2024-512884-30-00HUS-Yhtymae520
进行中（未招募）
不适用
A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer - SOLDEUCTR2007-002016-26-FIFinnish Breast Cancer Group3,000
进行中（未招募）
1 期
Comparison of two anti-HER2 agents plus chemotherapy with standard regimen as the treatments of breast cancer that expresses HER2Early HER-2 -positive breast cancerEUCTR2015-002323-25-FIFinnish Breast Cancer Group1,366
进行中（未招募）
1 期
Comparison of two anti-HER2 agents plus chemotherapy with standard regimen as the treatments of breast cancer that expresses HER2Early HER-2 -positive breast cancerEUCTR2015-002323-25-SEFinnish Breast Cancer Group1,366
进行中（未招募）
不适用
SOLDEUCTR2007-002016-26-SEFBCSG (Finish Breast Cancer Study Group)2,168